One very important issue faced by clinicians managing patients with prostate cancer is whether after initiating a man on a pure luteinizing-hormone-releasing hormone (LHRH) antagonist, he should then be switched to a longer-acting depot LHRH agonist. New evidence suggests that this therapeutic approach is both safe and effective.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
Journal of Biomedical Science Open Access 22 October 2017
-
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
BMC Health Services Research Open Access 13 June 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Garnick, M. B. & Mottet, N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. http://dx.http://dx.doi.org/10.1111/j.1464-410X.2011.10708.x.
McLeod, D. et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58, 756–761 (2001).
Mongiat-Artus, P. & Teillac, P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. 5, 2171–2179 (2004).
Klotz, L. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102, 1531–1538 (2008).
Crawford, E. D. et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186, 889–897 (2011).
Tombal, B. et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57, 836–842 (2010).
Schröder, F. H. et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 106, 182–187 (2010).
Dreicer, R., Bajorin, D. F., McLeod, D. G., Petrylak, D. P. & Moul, J. W. New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology 78 (5 Suppl.), S494–S498 (2011).
Moul, J. W. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. 103, 145–146 (2009).
Ryan, C. J. & Tindall, D. J. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol. 29, 3651–3658 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author has been a consultant for and received speakers bureau (honoraria) from Ferring.
Rights and permissions
About this article
Cite this article
Moul, J. Making the switch from LHRH antagonist to LHRH agonist. Nat Rev Urol 9, 125–126 (2012). https://doi.org/10.1038/nrurol.2012.5
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2012.5
This article is cited by
-
Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
Journal of Biomedical Science (2017)
-
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
BMC Health Services Research (2014)
